A Pivotal Clinical Investigation Confirming the Safety and Accuracy of the Glyconics-DS in Assessment of Glycated Nail Keratin in Individuals With Unknown Diabetes Status and Performance Evaluation of the Glyconics SW Package

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

486 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-13

Study Completion Date

2024-08-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main clinical study objective is to confirm the accuracy of the Glyconics-DS spectrometer when used in its intended medical purpose population, i.e., in individuals with unknown diabetes risk. Additionally, this investigation will serve as a pivotal performance evaluation for the associated software for correct delivery of the algorithm-based analysis of the individual diabetes risk. The study will be considered positive if the backend delivery of the chemometrics output is performed correctly as per the cloud-based analysis and its delivery represents the essential medical software to be evaluated in this investigation. The 'true' diabetes risk will be contrasted against values of an internal biomarker indicative of glycaemia, HbA1c, as measured based on standardised, certified methodology.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes

NCT07039357

Diabetes Mellitus Healthy

RECRUITING NA

Screening and Understanding of the Pre-diabetes: DECODIAB

NCT01739868

Pre-diabetes

UNKNOWN NA

Development of Minimally Invasive Methodology for Diabetyping to Personalise Treatment to Realise Remission and Reversal of Type 2 Diabetes

NCT06125119

Type 2 Diabetes

RECRUITING

Point-of-Care Testing in Outpatient Diabetes Care

NCT06684990

Diabetes

ACTIVE_NOT_RECRUITING NA

Non-Traditional Cardiovascular Risk Factors in Type 2 Diabetes Mellitus - Ancillary to VA Study of Glycemic Control

NCT00021944

Atherosclerosis Cardiovascular Diseases Diabetes Mellitus +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-diabetes Undiagnosed Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Mass-screening

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All participants

All individuals will be screened for their diabetes risk / status (if previously undiagnosed)

Group Type OTHER

Near-infrared (NIR)

Intervention Type DEVICE

Near-infrared assessment of glycated keratin in middle fingernail

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Near-infrared (NIR)

Near-infrared assessment of glycated keratin in middle fingernail

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Apparently healthy adults (≥18 years of age) with unknown diabetes status willing to participate in and provide a written consent for the study
* Willingness to undertake assisted assessment of glycaemia: by both the NIR spectral measurements in a chosen middle fingernail, and HbA1c (blood sample)
* Individuals with at least one visually assessed undamaged, intact (preferably middle) fingernail.

Exclusion Criteria

* Individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as:

* Severe forms of anaemia (diagnosed iron deficiency, sickle cell anaemia or similar).
* Haemoglobinopathies or atypical haemoglobin subtypes not detectable by regular (local) laboratory assays for HbA1c.
* Severe renal impairment (CKD stage III-IV) or decompensated hepatic disease.
* Severe Vitamin D deficiency (diagnosed or measured 25(OH)D3 \< 25 nmol/ml).
* Known severe immunodeficiency such as HIV, malignancy or other chronic condition significantly impacting assessment of glycaemia.
* Eating disorders (as per clinical assessment)
* Recent (within 28 days) blood donation
* Any other type of known diabetes than T2DM, if diagnosed (T1DM, GDM, MODY, etc.)
* Any structural, deviating and visually detectable deviations in the appearance of the (only/ to be assessed) middle fingernail potentially impacting the spectra measurement, including:

* nail dystrophy or deformity
* severe nail infections (onychomycosis causing visual changes in the appearance of the nail).
* rare hereditable conditions impacting the structure of keratin.
* mechanical damage or marks on the surface of the nail after removal of nail polish.
* use of acrylic or gel nail decoration and polish, which cannot be removed with acetone (use of acetone necessitates a 15 min post-removal wash-out time)
* Any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of HbA1c value.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes